Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04391322Active Not RecruitingPrimary

Assessment of CFTR-Modulator Treatment in Cystic Fibrosis Lung Disease Using Novel Structural and Functional MRI

Showing all 1 trials

Research Network

Active Sponsors

  • The Hospital for Sick Children1

Top Investigators

Related Conditions

  • Group 2 Stable Cf1
  • Group 3 Cf Participants Anticipated To Receive Cftrmodulator Therapy1
  • Group 4 48 Yo Cf Participants Starting Triple Combination Modulator Therapy1

Activity Timeline